Technical Analysis for SRPT - Sarepta Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical SRPT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | 2.44% | |
| Lower Bollinger Band Walk | Weakness | 2.44% | |
| Outside Day | Range Expansion | 2.44% | |
| Calm After Storm | Range Contraction | 1.10% | |
| NR7 | Range Contraction | 1.10% | |
| Lower Bollinger Band Walk | Weakness | 1.10% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is eteplirsen, an antisense PMO-based therapeutic, which is in Phase IIb clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
Biotechnology Biopharmaceutical Life Sciences Biology Infectious Diseases Rare Diseases Duchenne Muscular Dystrophy Therapeutic Gene Modulation Antisense RNA
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more SRPT news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 165.87 |
| 52 Week Low | 95.21 |
| Average Volume | 1,342,408 |
| 200-Day Moving Average | 127.5366 |
| 50-Day Moving Average | 139.2156 |
| 20-Day Moving Average | 139.337 |
| 10-Day Moving Average | 130.911 |
| Average True Range | 6.4452 |
| ADX | 31.23 |
| +DI | 10.09 |
| -DI | 33.9344 |
| Chandelier Exit (Long, 3 ATRs ) | 135.3644 |
| Chandelier Exit (Short, 3 ATRs ) | 134.3356 |
| Upper Bollinger Band | 159.9814 |
| Lower Bollinger Band | 118.6926 |
| Percent B (%b) | 0.15 |
| BandWidth | 29.63233 |
| MACD Line | -5.3574 |
| MACD Signal Line | -2.6316 |
| MACD Histogram | -2.7259 |
| Fundamentals | Value |
|---|---|
| Market Cap | 8.03 Billion |
| Num Shares | 64.2 Million |
| EPS | -2.34 |
| Price-to-Earnings (P/E) Ratio | -53.40 |
| Price-to-Sales | 53.98 |
| Price-to-Book | 6.98 |
| PEG Ratio | 231.25 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 129.56 | ||||
| Resistance 3 (R3) | 129.46 | 127.82 | 128.79 | ||
| Resistance 2 (R2) | 127.82 | 126.65 | 127.87 | 128.53 | |
| Resistance 1 (R1) | 126.39 | 125.93 | 127.11 | 126.49 | 128.28 |
| Pivot Point | 124.75 | 124.75 | 125.11 | 124.80 | 124.75 |
| Support 1 (S1) | 123.32 | 123.58 | 124.04 | 123.42 | 121.62 |
| Support 2 (S2) | 121.68 | 122.86 | 121.73 | 121.37 | |
| Support 3 (S3) | 120.25 | 121.68 | 121.11 | ||
| Support 4 (S4) | 120.35 |
